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Abstract 
 
One of the main putative causes of therapy refractory epilepsy in mesial temporal lobe 
epilepsy (MTLE) with hippocampal sclerosis is the overexpression of multidrug transporters 
(MDT) at the blood-brain barrier (BBB) (16). It steps up the removal of antiepileptic drugs 
(AEDs) out of the brain cells across the BBB resulting in a low concentration of AEDs within 
the target cells. Some of the mechanisms of AED resistance are most likely to be genetically 
determined. To obtain more information about the underlying pathophysiology of intractability 
in epilepsy we compared the global gene expression profile of human hippocampus and 
hippocampal-derived microvascular endothelial cells from MTLE with HS patients and 
controls. 
At the level of MDT a significant up-regulation was found for ABCB1 (P-gp), ABCB2, ABCB3 
and ABCB4, which was mainly related to endothelial cells. The data on the MDT were 
validated and extended by quantitative RT-PCR. Surprisingly, inflammatory factors such as 
interleukins (IL-1α, IL-1β, IL-6, IL-18) and cytokines (TNF- and TGF-1) were found to be 
up-regulated in hippocampal parenchyma. The overexpression of P-gp, IL-1β and IL-6 was 
also confirmed by immunohistochemistry (IHC). 
Our results suggest that complex expression changes of ABC-transporters may play a 
decisive role in pharmacoresistance in MTLE. Further studies on the new and unexpected 
overexpression of inflammatory cytokines may unlock hitherto undiscovered pathways of the 
underlying pathophysiology of human MTLE. 
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1. Introduction 
 
Mesial temporal lobe epilepsy (MTLE) with hippocampal sclerosis (HS) is the most common 
type of epilepsy in adults (34). HS consists of gliosis, neuronal loss and cell dispersion. As 
many as 75% of the patients with MTLE are considered to be resistant to drug therapy with 
AEDs. Pharmacoresitance is a common problem in neurological and psychiatric disorders 
which leads to a big distress among patients and family members. The long-term follow-up 
after selective amygdalohippocampectomy (sAHE) in the presence of severe HS showed a 
greater than 80% of patients becoming seizure free (35). The causes and mechanisms 
underlying drug resistance in MTLE are still badly understood, which hampers the 
development of new drugs and thus the availability of better treatment options (16), (21), 
(23), (25). The main factors which might contribute to the development of medically 
intractable MTLE are aetiology of epilepsy, the progression of seizure activity under drug 
therapy, changes in the targets of AEDs, abnormalities in the neuronal networks owing to 
damage in the epileptogenic focus during epileptogenesis, and changes in the drug-uptake 
across the BBB (18). Genetic factors may explain why patients with the same type of 
epilepsy respond differently to the same drug therapy. In recent years several putative 
mechanisms underlying drug resistance in epilepsy have been identified. One theory that has 
received considerable attention is the removal of AEDs from the epileptogenic tissue through 
overexpression of multidrug transporters at the BBB. This theory is biologically feasible and 
can partly explain drug-resistance. Although MTLE is usually not regarded as a 
neuroimmunological disease, pro-inflammatory cytokines and chemokines may play a role in 
seizure onset (7), (11). It has also been reported in experimental models of limbic seizures 
that there is rapid and transient increase of IL-1β, IL-6 and TNF-α mRNA in the hippocampus 
and that intrahippocampal injection of IL-1β has a detrimental effect on seizures (28). 
Furthermore, a polymorphism in the IL-1β gene has been associated with MTLE-HS 
compared to patients without sclerosis and nonepileptic controls (5), (12). Febrile seizures, 
particularly complex febrile seizures and status epilepticus during early childhood have been 
associated with hippocampal sclerosis and overexpression of IL-1β (9). The relevance of 
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sclerotic hippocampus in seizure maintenance and therapy refractoriness, has led to us to 
investigate the mRNA expression profile of the sclerotic hippocampus in order to obtain a 
comprehensive view of this particular pathology at the molecular level. Accordingly, we used 
a DNA microarray approach. The main aim of this study was to identify those genes which 
may be involved in the pathogenesis of MTLE-HS. A separate comparison was performed for 
mRNAs extracted from the entire tissue and from MVECs prepared from the resected tissue. 
In the interpretation and discussion of the data we focused on the multidrug-transporter 
overexpression theory and on the genes which were found to be among the most 
overexpressed in sclerotic hippocampus. 
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2. Methods 
 
2.1. Surgical specimens  
Clinical specimens were obtained from ten caucasian patients with chronic pharmaco-
resistant MTLE, who underwent surgical treatment at the Department of Neurosurgery, 
University Hospital Zurich (Table 1). Surgical removal of the hippocampus was clinically 
indicated in every case. The specimen was obtained by selective amygdalohippo-
campectomy (sAHE). With this surgical approach, parts of the amygdala, the hippocampus, 
and the anterior portion of the parahippocampal gyrus (Gph) are selectively removed. All 
tissues were diagnosed by two pathologists at the Department of Neuropathology, University 
Hospital Zurich. The hippocampus and the Gph were examined and separately rated for the 
presence and severity of hippocampal sclerosis (HS) based on the extent of gliosis and 
neuronal loss (mild, marked, and severe). All hippocampal regions revealed HS with various 
degrees of gliosis and neuronal loss. All analyses were conducted in accordance with the 
Declaration of Helsinki and approved by the Ethics Committee of the Canton of Zurich. 
Informed written consent was obtained from all patients. Control human brain hippocampus 
total RNA were commercially purchased by Ambion® (Ambion, Inc. Texas, USA). The 
autopsy controls (n=3; 45,5±10 years old; 2 female, 1 male; Caucasians) had no history of 
brain-related disease and suffered sudden death without associated brain damage. Autopsy 
was rapidly performed with a short postmortem delay. Autopsy hippocampi were dissected 
and immediately collected in RNA-Later tubes and frozen until processing. Totally RNA was 
isolated using the modified version of Ambion’s RNA KIT for RNA-Isolation and RNA was 
stored in 1mM sodium citrate (pH 6.4) at -70°. 
 
2.2. Isolation of human brain-derived microvascular endothelial cells (MVEC) 
MVEC were isolated as described by (19), (22). Briefly, ependym, large vessels and pia 
membrane were dissected away with the help of a microscope, and the remaining tissue 
minced and homogenized with a 10 ml-syringe in 10 ml MCDB 131 medium (Gibco, 
Invitrogen, Basel, Switzerland); containing 2% FBS (PAA Laboratories, Linz, Austria); 16 
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U/ml heparin (Sigma, Fluka Chemie, AG Buchs, Switzerland); 20 l BBE; 5 l hEGF; 5 l 
hydrocortison; 5 l FGF (all from Cell System Inc. Kirkland. WA); 50 l ECGS (Serva, 
Heidelberg, Germany); 500 l gentamycin (Sigma). The tissue was dissociated in a glass 
flasklin dispase II solution (Roche, Rotkreuz, Switzerland) to a final concentration of 0.096 
U/ml and the solution was placed in a water bath at 37°C and stirred for approximately 1 h. 
The homogenate was centrifuged (1,000xg, 10 min, 4°C) and the supernatant was removed. 
The pellet was dissolved in 2 ml MCDB 131 medium, containing 20% dextran, (Sigma) and 
gently homogenized with a fire-polished pipette and centrifuged (1,700xg, 10 min, 4°C). The 
top layer containing most of the myelin was discarded. The pellet was resuspended in MCDB 
131, containing 2% FBS medium, layered on 2 ml 13% dextran and again centrifuged 
(1,700xg, 10 min, 4°C) to remove the remaining myelin. The pellet was solubilized in 1 mg/ml 
collagenase/dispase (Roche) and 0.05 mg/ml DNase I (Sigma) and stirred for 1 h. The cells 
were pelleted (380xg, 10 min, 4°C), washed with MCDB 131 containing 2% FBS medium and 
the pellet was finally placed in 1 ml QIAzol lysis reagent (Qiagen, Basel, Switzerland) frozen 
and kept at –70°C until further processing. 
 
2.3. Processing of hippocampal tissues 
Immediately after surgery hippocampal specimen from epileptic patients were stored in 
RNAlater stabilization reagents (Qiagen) in order to prevent degradation of RNA. The 
samples were stored at 4°C overnight and subsequently frozen and kept at –70°C until 
further processing. 
 
2.4. Isolation and analysis of RNA 
Total RNA from isolated MVEC was extracted by using QIAzol lysis reagent according to the 
manufacturer’s protocol. The isolated MVEC were placed in 1 ml QIAzol reagent, frozen and 
kept at –70°C. After thawing, 0.2 ml dichlormetane was added and the samples were 
centrifuged (12000g, 15 min, 4°C) for phase separation. The RNA from the upper aqueous 
phase was precipitated by mixing with 0.5 ml isopropyl alcohol. After 10 min incubation the 
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samples were centrifuged (12,000xg, 10 min, 4°C) and the RNA pellet was washed with 1 ml 
75% ethanol. At the end of the procedure the RNA was briefly dried and then dissolved in 
RNase-free water. The hippocampal biopsies were thawed, and placed in 1 ml QIAzol 
reagent for RNA isolation and processed according to the protocol RNeasy Lipid Tissue Mini 
Handbook (Qiagen). The quality of the isolated RNA was determined by NanoDrop ND 1000 
(NanoDrop Technologies, Delaware, USA) and a Bionalyser 2100 (Agilent Technologies, 
Basel, Switzerland). Only those samples with a 260 nm/280 nm ratio between 1.8-2.1 and a 
28S/18S ratio within 1.5-2 were processed further and investigated. Control human 
hippocampal RNA was commercially purchased (Ambion Ltd., Huntingdon, UK). 
 
2.5. cRNA preparation 
3 µg and 100 ng of total RNA per sample were reverse-transcribed into double-stranded 
cDNA with one-cycle and two cycle cDNA synthesis kit (Affymetrix Inc., P/N 900431, Santa 
Clara, CA), respectively. The double-stranded cDNA was purified using a Sample Cleanup 
Module (Affymetrix Inc.). The purified double-stranded cDNA was in vitro transcribed (IVT) in 
the presence of biotin-labeled nucleotide using an IVT Labeling Kit (Affymetrix Inc.) and the 
biotinylated cRNA was purified using a Sample Cleanup Module (Affymetrix Inc., P/N 
900371). The quality and quantity of biotin-labeled cRNA was determined using NanoDrop 
ND 1000 and Bioanalyzer 2100. 
2.6. Array hybridization 
15 µg of biotin-labeled cRNA was fragmented randomly to 35–200 bp at 94°C in 
fragmentation buffer (Affymetrix Inc., P/N 900371) and were mixed in 300 µl of hybridization 
buffer containing a hybridization control cRNA and control Oligo B2 control (Affymetrix Inc., 
P/N 900454); 0.1 mg/ml herring sperm DNA; and 0.5 mg/ml acetylated bovine serum albumin 
in 2-(4-morpholino)-ethane sulfonic acid (MES) buffer, pH 6.7, before hybridization to 
GeneChip® Human Genome U133 Plus2.0 arrays, which contains 47000 transcripts, for 16 
hours at 45°C. Arrays were then washed using an Affymetrix Fluidics Station 450 EukGE-
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WS2v5_450. Affymetrix GeneChip Scanner 3000 (Affymetrix Inc.) was used to measure the 
fluorescent intensity emitted by the labeled target. 
 
2.7. Microarray data analysis 
Raw data processing was performed using the Affymetrix Genespring software (Silicon 
Genetics, California, USA). After hybridization and scanning, probe cell intensities were 
calculated and summarized for the respective probe sets by means of the MAS5 algorithm 
(10). To compare the expression values of the genes from chip to chip, global scaling was 
performed, which resulted in the normalization of the trimmed mean of each chip to target 
intensity (TGT value) of 500 as detailed in the statistical algorithms description document of 
Affymetrix. Quality control measures were considered before performing the statistical 
analysis. These included adequate scaling factors (between 1 and 3 for all samples) and 
appropriate numbers of present calls calculated by application of an algorithm. The efficiency 
of the labelling reaction and the hybridization performance was controlled with the following 
parameters: present calls and optimal 3' /5' hybridization ratios (around 1) for the 
housekeeping genes (GAPDH and ACO7), for the poly A spike in controls and the 
prokaryotic control (BIOB, BIOC, CREX, BIODN). Analysis was performed by setting controls 
sample data set to zero and filtering and utilizing only genes with transcripts flagged ‘present’ 
or ‘marginal’. Gene transcripts with a difference of 2-fold or greater ‘induction’ or ‘reduction’ 
when compared to controls were subsequently annotated and grouped according to their 
molecular and cellular function. 
 
2.8. Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted from hippocampal biopsies and MVEC using QIAzol reagent 
(Qiagen) according to the manufacturer’s protocol. Quantification of ABC transporters was 
performed by a TaqMan Low Density Array, which is based on an Applied Biosystems 
7900HT Micro Fluid Card. The method allows simultaneous analysis of 47 human ABC 
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transporters and the reference gene 18S rRNA in two replicates of four different samples per 
run (14). 
 
2.8. Immunohistochemistry and Immunofluorescence 
The following antibodies were used for IHC MRP1 (MRP1); MRP2 (M2I-4); MRP3 (M3II-9); 
MRP4 (M4I-80); MRP5 (M5I-1), all from Alexis, Lausen, Switzerland and IL-1β (H-153) and 
IL-8 (ab-16223), both from Abcam, UK. Hippocampal samples were fixed in formalin 4% and 
embedded in paraffin. Sections were cut at thickness of 2 μm, mounted on gelatinized glass-
slides, deparaffinized, rehydrated and rinsed (Tris puffer, pH=7.4). The slides were pre-
treated for antigen retrieval in 10 mM Na-citrate, pH 6, in microwave for 10 min. 
Subsequently, sections were treated with 0.3% H2O2 in methanol for 10 min to abolish 
endogenous peroxidase activity and with 2% normal goat serum in Tris for 20 min to block 
non-specific igG binding sites. The primary antibody were diluted in Tris (1:50) and applied 
overnight at 4°C. After rinsing in Tris, the sections were incubated with biotin labelled anti-
mouse IgG (1:100) or anti-rat IgG (1:100) for 1 hour at RT. After washing in Tris, the sections 
were incubated with biotin-avidin complex, containing peroxidase (Dako) and washed and 
staining with haematoxylin for nuclear staining, dehydrated and cleared in xylene and cover 
glass mounted with eukitt (Erne-Chemie, Switzerland). 
Immunolabeling of MTLE tissue: 20-µm sections were obtained using a vibrating microtome 
(VT 1000S, Leica, Heilderberg, Germany) and processed as free-floating sections for double 
immunolabeling with mouse anti-P-gp C494 (Signet Laboratories, Dedham, MA, diluted 1:10 
to 1:40 in BB) and rabbit anti-GFAP (diluted 1:1 in BB; prediluted antibody from ImmunoStar, 
Hudson, WI). The incubation steps were as follows: 1) 30 min in BB; 2) 30 minutes in 0.5% 
Triton X-100 in PBS; 3) 1 hour in a mixture of the primary antibodies at RT; and 4) 1 hour in 
the fluorophore conjugates goat anti-mouse and goat anti-rabbit IgGs at RT (diluted 1:200 in 
BB; Alexa Fluor 488 and 555 respectively; Invitrogen) at RT. The sections were washed 3 
times for 10 min in PBS between each step and counterstained with TOPRO-3 (diluted 1:10K 
in PBS; Invitrogen) added to the final wash. The sections were then transferred onto 
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Vectabond treated slides (Vector Laboratories), carefully drained, coverslipped in 
Vectashield mounting medium (Vector Laboratories), and sealed with nail varnish. 
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3. Results 
The GeneChip expression analysis was performed from control hippocampi (n=3), 
hippocampal MTLE biopsies (n=8) and isolated MVECs (n=2) thereof. A total of 27,000 out of 
54,000 mRNA transcripts of known or predicted function were found to be present in all 
samples. The expressed genes were normalized and compared with control. Gene 
transcripts with >2-fold induction or reduction were analyzed. The comparison of the gene 
expression profiles of AHEs, MVECs and controls is shown in the multidimensional 
hierarchical cluster analysis (Fig. 1). This analysis revealed remarkable differences between 
the three groups. When AHEs were compared with controls, a total of 1,253 genes were 
found to be significantly up-regulated and 637 genes down-regulated. Among the many up-
regulated genes we found also GFAP (7.6-fold) as a bona fide marker for astrogliosis. The 
comparison between MVEC and controls revealed 7,862 up-regulated and 9,504 down-
regulated genes. These much higher numbers compared to AHE reflect enrichment of 
endothelial mRNA upon eliminations of glial genes from the highly purified MVEC population. 
Various multidrug transporters of the ATP-binding cassette protein, subfamilies A (ABCB) 
and B (ABCC) were found to be overexpressed in AHEs and MVECs compared to the control 
group. A significant up-regulation of ABCB1/P-gp, ABCB2 and ABCB3 was found in MVECs 
of epileptic hippocampi (Table 2). Among the ABCC transporters, only ABCC4 was 
significantly up-regulated in both AHEs and MVECs (Table 2). These data were validated by 
quantitative RT-PCR analysis, as summarized in Table 3.  The trend which was found by 
micro array analysis became statistically significant by RT-PCR for P-gp, MRP-2 and MRP4 
(Tab. 3). As we had to deal with a large number of differentially expressed genes we 
evaluated those genes which were found to be highly overexpressed in epileptic patients 
compared to controls. Surprisingly, immunological factors such as cytokines, were 
significantly up-regulated in AHEs (n=8) compared to controls (n=3). This includes in pro-
inflammatory interleukins (IL-1α, IL-1β, IL-6 and IL-18), and cytokines (TNF-α and TGFβ-1) 
as shown in Figure 2. 
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The immunohistochemistry staining of human hippocampal section for IL-1β revealed a 
strong expression, mainly localized at the cerebrovascular unit from epileptic hippocampus 
(Fig. 3 C and D); and staining for IL-6 showed positive expressing cells to be evenly 
distributed in vessels, neurons and glial cells of epileptic hippocampus (Fig. 3F). 
At the protein level high P-gp expression was found in an MTLE patient which was restricted 
to the luminal side of MVECs and not detectable on GFAP-positive astrocytes (Fig. 4A and 
C). In a control patient a capillary (Fig. 4D-F) and a small arteriole (Fig 4G) showing P-gp 
expression at lower level and mainly on the luminal front (Fig. 4E, F, H and I). 
The morphology of cultured MVECs derived from epilepsy patients had a coblestone 
morphology with some spindleform-like, elongated cells (Fig. 5A) which was also seen in 
control MVEC cultures (data not shown) and their purity was demonstrated by expression of 
the endothelial marker CD105 (Fig. 5B and C). 
Interestingly cultured MVECs isolated from MTLE patients revealed by flow cytometry an 
enhanced P-gp expression in comparison to controls (Fig. 5B and C). In contrast no 
difference was found in their level of MRP1 expression. These data are consistent with the 
findings on the mRNA level. 
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4. Discussion 
In our study resected hippocampi and hippocampal MVECs, forming the BBB from epileptic 
patients were evaluated for their global gene expression profile. Our analysis was based on 
the “multitransporter up-regulation hypothesis". We also singled out those genes that were 
found highly up-regulated. 
In examining the gene expression profile of the multidrug transporters, we included all 
transporters that have been described in the literature; 13 ABCC and 12 ABCB transporters. 
Some of them have been associated with medically intractable epilepsy: ABCB1/P-gp. (1), 
(8), (13), (24), (26); MRP1 and MRP2 (1), (8), (13); MRP3 and MRP5 (8). Most of these 
findings are based on IHC. However, Dombrowski et al. performed a gene expression 
analysis of MVEC isolated from human epileptogenic hippocampi and discovered an up-
regulation of P-gp, MRP2, -3 and -5, which is partly consistent with our findings. In addition 
we observed an up-regulation of ABCB2, ABCB3, ABCB4 and MRP4. Until now these 
transporters have not been identified as being overexpressed in epileptogenic hippocampi, 
suggesting that of the list of gene products contributing to the "transporter hypothesis" may 
need to be enlarged. 
With regard to the localization of these transporters, our results show an up-regulation, 
mainly in endothelial cells. Several studies have addressed the question of where these 
transporters are exactly localized; however the answers are still highly controversial (luminal 
versus basolateral or even both). 
At the protein level, IHC of hippocampal sections revealed that P-gp and MRP1-5 were 
largely confined to the endothelial cells of the hippocampus. The overexpression of these 
genes was validated by quantitative realtime RT-PCR and the results were compared to that 
of the gene array. No significant differences were found by gene array when the averaged 
values of P-gp of individual epileptic patients and controls were compared. However, P-gp 
values obtained by RT-PCR revealed a statistically significant difference between them. The 
same situation was also observed by comparing the MRP4 values. This finding suggests that 
the RT-PCR method is more sensitive; further support for this is given by the threshold 
 14 
cycles (CT-values). When comparing MRP1, MRP2, and MRP3, no significant differences 
were obtained between the two methods. In contrast, a statistical significance for MRP5 was 
found by gene array analysis, but not by the RT-PCR analysis. 
Unexpectedly, we observed a strong up-regulation of various cytokines (IL-1α, IL-1β, IL-6, IL-
18, TNF- and TGF-1) in the hippocampus of epilepsy patients. The fact that MTLE-HS has 
not been considered to be an immunological disorder makes this finding even more 
interesting. Only few papers addressed a possible link between immunology and epilepsy, 
using different approaches. Two studies have been published on the gene expression profile 
of hippocampus in MTLE (3), (4). In one of the studies the mRNA expression was compared 
in the hippocampi of three patients with sclerosis and three without, using a small array 
representing 588 genes. This study revealed 9 overexpressed genes and 12 underexpressed 
genes. Among these genes are those associated with gliosis (GFAP), cell death/survival, and 
neuronal plasticity, but none associated with inflammation (3). In the second study, five 
sclerotic hippocampi from MTLE patients were analysed, using the Affymetrix GeneChip 
U133A (4). Unfortunately, this study does not report on the full expression pattern in these 
specimens, but only the expression pattern that was also present in the hippocampi from rats 
having pilocarpine-induced seizures. It is important to mention that the lack of a suitable 
control ("healthy" hippocampus) makes it difficult to interpret these results. 
With respect to the link between MTLE and immunology, one of the most remarkable findings 
is the role of IL-1β in the development of febrile seizures in animal models as well as the 
assumption that a polymorphism of IL-1β at position -511 may favour a high production of IL-
1β in patients with MTLE-HS, possibly a major trigger for the development of HS (12). In 
another study the role of cytotoxic T cells and auto-antibodies against neurons in the brain in 
Rassmussen encephalitis was examined suggesting an immunotherapy as a treatment 
approach (6). 
In a recent article possible pathways underlying neuronal death in HS have been postulated, 
including the participation of cytokines and chemokines, leading to a disturbance of the 
glutamatergic system, and subsequently to the persistence of seizures by chronic neuronal 
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over-excitation (20), (28), (30), (31). Among the different factors potentially involved in the 
molecular pathway underlying glutamate release from astrocytes, chemokines, chemokine 
receptors, IL-1β, and prostaglandin E2 have been found to be highly up-regulated in both 
epileptogenic hipppocampus and MVEC. In experimental models and in clinical cases of 
epilepsy pro-inflammatory and anti-inflammatory cytokines have been described in brain and 
plasma after seizure induction. Experimental findings demonstrated that pro-inflammatory 
cytokines IL-1β, IL-6 and TNF-α in microglia and astrocytes are increased and followed by a 
cascade of downstream inflammatory events which may recruit cells of the adaptive immune 
system (17), (29). In addition to inflammatory disease, recent evidence shows the activation 
of innate immune system and associated inflammatory reactions in epilepsy may modulate 
some of the molecular and structural changes occuring during and after seizure activity (29). 
Moreover experimental strategies aiming to block CNS or systemic inflammatory pathways 
reduce status epilepticus duration and seizure frequency (27). 
Nevertheless, little is known about the possible underlying mechanisms which might be 
responsible for the fact that inflammatory factors are strongly overexpressed (2). How 
inflammatory reactions intrinsic to the brain compared with those mediated by peripheral 
immune cells can be contributed to the epileptogenesis, is poorly understood (32). BBB 
failure might be a link between these two mechanisms. 
In summary, whether these findings contribute to the persistence of seizures despite 
treatment with AEDs, or whether this event must be regarded as an epiphenomenon, is 
currently an open issue. It remains elusive, however, if such changes are cause or 
consequences of the disease. Since the underlying pathophysiology of MTLE-HS remains an 
issue of debate, more research is needed with the common goal of finding new targets and 
therapeutioc strategies. The findings that inflammatory mediators contribute to the onset and 
recurrence of seizures in experimental models, as well as the presence of inflammatory 
molecules in human epileptogenic tissue, does highlight the possibility of targeting specific 
inflammation-related pathways to control seizures that are otherwise resistant to the 
available AEDs. Drugs that block IL-1 actions have entered clinical trials as potential 
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therapeutics for autoimmune and inflammatory pathologies, and may also have therapeutic 
potential in refractory epilepsies associated with proinflammatory processes in the brain (33). 
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Figure legends 
 
Figure 1 
Cluster analysis of the gene expression patterns of isolated MVECs (n=2) and AHEs (n=8) 
from patients with MTLE after selective amygdalohippocampectomy (sAHE) and control 
hippocampal tissue specimens (n=3). The analysis was performed using GeneSpring 
software. The analysis included all differentially expressed genes expressed in 
oligonucleotide microarray analysis (Affymetrix, HG-U133Plus2.0). Each horizontal colour 
bar denotes the intensity of expression of a particular gene in a distinct sample relative to the 
mean expression value of all samples. Yellow denotes little or no change, red denotes 
increased expression, and blue denotes decreased expression. 
AHE (amygdalohippocampectomy); MVEC (microvascular endothelial cells); and C (control). 
 
Figure 2 
Relative gene expression of IL-1α, IL-1β, IL-6, IL-18, TNF- and TGF-1 of control 
hippocampal tissues (n=3) and AHEs (n=8). The results of gene array analysis were 
calculated by GeneSpring software. Control mean values were set to one and the fold 
change of the AHE means calculated. 
 
Figure 3 
Photomicrographs of IL-1β (A, B, C, D) and IL-6 (E, F) in hippocampus (dentate gyrus) from 
a control (A, B, E) and epileptic patient (no. 5) (C, D, F). Only a weak IL-1β staining was 
found in control patient (A, B, E) in contrast to the epileptic patient (C, D, F). The staining 
was mainly confined to the neurovascular unit. Figures show transverse sections at different 
magnifications (A, C, E: x 4; B, D and F: x 20). Scale bar: 100 m. Isotype antibody controls 
are shown as inserts in A and C 
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Figure 4 
Laser scanning confocal microscopy of P-gp and GFAP expression in MTLE (A-C) and 
control (D-I) tissue sections. (A-C) High expression of P-gp which appears restricted to the 
luminal side of microvascular endothelial cells (B, C; arrows) and is not detectable on GFAP-
positive astrocytes (A,C). A control capillary (D-F) and a small arteriole (G-I) showing P-gp 
expression preferentially localized on the endothelial luminal front (E, F, H, I; arrows) and 
absence of P-gp in the GFAP-positive perivascular astrocytes (D, F, G, I). Note in (H, I) the 
expression of P-gp on smooth muscle cells (arrowheads) . Scale bars: A-F, 10 µm; G-H 20 
µm. 
 
Figure 5 
P-glycoprotein and MRP-1 expression of brain-derived microvascular endothelial cells 
(MVECs) of an MTLE and control patient. 
Morphology of primary hippocampal MVECs after 10 days in culture from an epileptic patient 
(A). Confluent MVECs exhibit a coblestone morphology with some spindleform-like, 
elongated cells. Scale bar: 60 m. 
P-gp and MRP-1 expression was assessed by flow cytometry of primary hippocampal 
MVECs isolated either from a patient who underwent selective amygdalohippocampectomy 
(sAHE) (B) or a control tissue specimen (C). 
The expression of the endothelial marker endoglin (CD105) was shown to proof the purity of 
the MVEC cultures (B and C). 
The open profiles indicate the specific antibodies, and the filled profiles the isotype 
antibodies. 
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